Subgroup considerations This recommendation is the same for HIV-negative people and for people living with HIV. The data used in this review examined only patients with drug-susceptible pulmonary TB who had no extenuating circumstances – such as adverse reactions which might require modification of the dosing schedule. Children were not considered specifically in this review. However, there is no biologically plausible reason why this recommendation should not also apply to children. It is recommended that all children receive daily dosing of TB medications during the intensive and continuation phases of therapy for the same reason as adults. See WHO’s 2014 guideline Guidance for national tuberculosis programmes on the management of tuberculosis in children (18) for recommendations on the daily dosing of children with DS-TB. Implementation considerations There are no new implementation considerations as the recommended daily treatment is already widespread practice. However, intermittent dosing is still used in some countries. In such exceptional cases, implementation of the recommendation to use exclusively daily dosing in the intensive and continuation phases of TB therapy is likely to have implications for medication procurement, practitioner training, change of programme practice and patient support.